Semax comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-21. Numbers and descriptions here follow the published literature rather than marketing material.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
| Property | Value | Notes |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Heptapeptide; ACTH(4-10) analog extended at C-terminus |
| Molecular mass | ~813.9 Da | Free peptide, unmodified |
| Appearance | White to off-white powder | Typical lyophilized solid |
| Solubility | Soluble in water and saline | Also soluble in common aqueous buffers |
| Storage (solid) | -20 °C, desiccated | Protect from moisture and repeated thawing |
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
This suggested that it was evolutionarily more difficult to increase the UV-sensitivity of the eyes of the males than to increase the UV-signals emitted by the females. Many insects use the ultraviolet wavelength emissions from celestial objects as references for flight navigation. A local ultraviolet emitter will normally disrupt the navigation process and will eventually attract the flying insect.
The chemical names were based on the side chains of the compounds. In 1948, Chain introduced the chemical names as standard nomenclature, remarking that this would "make the nomenclature as far as possible unambiguous". In Kundl, Tyrol, Austria, in 1952, Hans Margreiter and Ernst Brandl of Biochemie developed the first acid-stable penicillin for oral administration, penicillin V. American chemist John C. Sheehan at the Massachusetts Institute of Technology (MIT) completed the first chemical synthesis of penicillin V in 1957. Sheehan had started his studies into penicillin synthesis in 1948, and during these investigations developed new methods for the synthesis of peptides, as well as new protecting groups—groups that mask the reactivity of certain functional groups. Although the initial synthesis developed by Sheehan was not appropriate for mass production of penicillins, one of the intermediate compounds in Sheehan's synthesis was 6-aminopenicillanic acid (6-APA), the nucleus of penicillin. An important development was the discovery of 6-APA itself. In 1957, researchers at the Beecham Research Laboratories in Surrey isolated 6-APA from the culture media of P. chrysogenum. 6-APA was found to constitute the core nucleus of penicillin (and subsequently many β-lactam antibiotics) and was easily chemically modified by attaching side chains through chemical reactions. The discovery was published in Nature in 1959. This paved the way for new and improved drugs as all semisynthetic penicillins are produced from chemical manipulation of 6-APA.
Cold Storage is a Singaporean multinational supermarket company. Its parent company also operates Market Place stores, now branded as Cold Storage Fresh, as well as the Giant hypermarket brand, and has various other supermarkets around Asia including Hero and Wellcome. Founded in 1903 as the Singapore Cold Storage Company, Cold Storage was one of the first supermarkets in Singapore to offer its merchandise online in 1997. The number of regular customers has since grown from 6,000 in 1998, to more than 15,000 in 2012. In 1992, DFI purchased the company. It was sold to Macrovalue in 2025. SGS has awarded a HACCP certification to Cold Storage, for its quality and integrity in food safety. As of 2025, Cold Storage operates 45 stores in Singapore across the country.
The GHRL gene produces mRNA which has four exons. Five products arise: the first is the 117-amino acid preproghrelin. It is homologous to promotilin; both are members of the motilin family. It is cleaved to produce proghrelin which is cleaved to produce an unacylated 28-amino acid ghrelin and an acylated C-ghrelin. Obestatin is presumed to be cleaved from C-ghrelin. Ghrelin only becomes active when caprylic (octanoic) acid is linked posttranslationally to serine at the 3-position by the enzyme ghrelin O-acyltransferase (GOAT) to form a proteolipid. It is located on the cell membrane of ghrelin cells in the stomach and pancreas. The non-octanoylated form is desacyl ghrelin. It does not activate the GHS-R receptor but does have other effects: cardiac, anti-ghrelin, appetite stimulation, and inhibition of hepatic glucose output. Side-chains other than octanoyl have also been observed: these can also trigger the ghrelin receptor. In particular, decanoyl ghrelin has been found to constitute a significant portion of circulating ghrelin in mice, but as of 2011 its presence in humans has not been established.
Sources: en.wikipedia.org
Triple-decker complexes are composed of three Cp anions and two metal cations in alternating order. The first triple-decker sandwich complex, [Ni2Cp3]+, was reported in 1972. Many examples have been reported subsequently, often with boron-containing rings.
Those who have used topical corticosteroids over a prolonged period of time Those who have used corticosteroids to cover a large surface area Those with broken skin barrier or extensive abrasions Those who have recently undergone stress (such as illness, trauma, surgery) Children under the age of 12 HPA axis suppression is preventable by supplementation with glucocorticosteroids. If HPA axis suppression occurs, it is often reversed shortly after discontinuation of treatment.
Somali is the official language of Somalia and Arabic is the second language. The Somali language is the mother tongue of the Somali people, the most populous ethnic group. It the best documented member of the Cushitic branch of the Afro-Asiatic language family. Somali dialects are divided into Northern, Benadir and Maay. Northern Somali is the basis for Standard Somali. Benadir is spoken on the Benadir coast, being the most spoken dialect. The coastal dialects have additional phonemes that absent in Standard Somali. Maay is principally spoken by the Rahanweyn clan in south. Many writing systems have been used for Somali. Of these, the Somali alphabet is the most widely used, being the official writing script since the Supreme Revolutionary Council introduced it in 1972. Other orthographies that have been used for centuries for writing Somali include the long-established Arabic script and Wadaad's writing.
When in 1863 the Association of Serbian Philology commemorated the death of Cyril a thousand years earlier, its president Dimitrije Matić talked of the creation of an "ethnically pure" Slavonic people, "With God’s help, there should be a whole Slavonic people with purely Slavonic faces and of purely Slavonic character." After World War I the creation of the Kingdom of Yugoslavia, under Serbian royalty of the Karađorđević dynasty, united most Southern Slavic-speaking nations regardless of religion and cultural background. The only ones they did not unite with were the Bulgarians. Still, in the years after the Second World War, there were proposals to incorporate Bulgaria into a Greater Yugoslavia thus uniting all south Slavic-speaking nations into one state. The idea was abandoned after the split between Josip Broz Tito and Joseph Stalin in 1948. This led to some bitter sentiment between the people of Yugoslavia and Bulgaria in the aftermath. At the end of the Second World War, the Partisans' mixed heritage leader Josip Broz Tito became Yugoslav president, and the country become a socialist republic, with the motto of "Brotherhood and Unity" between its various Slavic peoples.
An example of a depsipeptide drug is the anticancer agent romidepsin, a known histone deacetylase inhibitor (HDACi). It was first isolated as a fermentation product from the soil bacterium Chromobacterium violaceum by the Fujisawa Pharmaceutical Company. Streptogramins, specifically streptogramin B, are depsipeptides that bind to the 50S subunit of bacterial ribosomes. Etamycin was shown in preliminary data in 2010 to have potent activity against MRSA in a mouse model. Several depsipeptides from Streptomyces exhibit antimicrobial activity. These form a new, potential class of antibiotics known as acyldepsipeptides (ADEPs). ADEPs target and activate casein lytic protease (ClpP) to initiate uncontrolled peptide and unfolded protein degradation, killing many Gram-positive bacteria. Depsipeptides can be formed through a Passerini reaction.
Sources: en.wikipedia.org
Feminizing hormone therapy, also known as transfeminine hormone therapy, is a form of gender-affirming hormone therapy (GAHT) which change the primary and secondary sex characteristics of transgender people from masculine to feminine. It is one of the two common type of GAHT the other being masculinizing hormone therapy) and is used to treat transgender women and non-binary transfeminine individuals. Some others, in particular intersex people, but also some non-transgender people, take this form of therapy according to their personal needs and preferences. The purpose of the therapy is to cause the development of the secondary sex characteristics of the desired sex, such as breasts and a feminine pattern of hair, fat, and muscle distribution. It cannot undo many of the changes produced by naturally occurring puberty, which may necessitate surgery and other treatments to reverse (see below). The medications used for feminizing hormone therapy include estrogens, antiandrogens, progestogens, and gonadotropin-releasing hormone modulators (GnRH modulators). Feminizing hormone therapy has been empirically shown to reduce the distress and discomfort associated with gender dysphoria in transfeminine individuals.
(2026) reconstruct the demographic history of late Neanderthals on the basis of data from mitochondrial DNA, reporting evidence indicating that nearly all late Neanderthals from Europe belonged to a single mitochondrial DNA lineage, likely as a result of expansion across Europe from a refugium in southwestern France, and evidence of rapid decline in the effective population size of late Neanderthals shortly before their extinction; Sánchez Goñi & d'Errico (2026) link the presence of the refugium in southwestern France to the climatic configuration affecting western Europe 76,000 to 68,000 years ago. Bossoms Mesa et al. (2026) reconstruct the genetic diversity of late Neanderthals from Belgium and France, finding no evidence of mating among close relatives or genetic deterioration prior to Neanderthal extinction. Yousefi et al. (2026) study changes in suitability and connectivity of Neanderthal habitat through time, and find no evidence of habitat fragmentation caused by climate changes before Neanderthal extinction. Baykara et al. (2026) report evidence of sequential occupation of the Üçağızlı II Cave (Turkey) by Neanderthals and modern humans, and evidence of cultural continuity between members of the two human lineages occupying the site. Schoenemann et al. (2026) interpret differences in brain anatomy of Neanderthals and modern humans as falling within the range of differences between modern human populations, and find no evidence of significang cognitive differences between Neanderthals and modern humans that might have contributed to Neanderthal extinction.
=== IATSE strike === Problems kept coming on July 16, when thirty to thirty-five crew members went on strike to demand better wages and benefits, under encouragement from the IATSE union, whose local representative warned that the dispute would cost The Stone Group an additional $40,000 per day. The production was sanctioned by the Directors Guild of America and Screen Actors Guild, but did not recognize other labor groups. As such, the film's technicians were signed to a flat fee. Filming was again suspended but, since Mississippi was a right-to-work state, the concerned workers were summarily fired and fifty new ones were brought in. This included cinematographer Leonetti, who was replaced by Alexander Gruszynski and complained that he stood to lose $50,000 in wages. Meanwhile, on July 17, Bosworth was officially released from his NFL contract by the Seattle Seahawks, although this was expected due to his persistent shoulder issues, and he already considered himself an actor first.
Paul Berg, a Nobel laureate in chemistry, wrote to the Senate that "Quackery will always prey on the gullible and uninformed, but we should not provide it with cover from the NIH," and called the office "an embarrassment to serious scientists". Allen Bromley, then-president of the American Physical Society, similarly wrote to Congress that the OAM had "emerged as an undiscriminating advocate of unconventional medicine. It has bestowed the considerable prestige of the NIH on a variety of highly dubious practices, some of which clearly violate basic laws of physics". Leon Jaroff, writing for The New York Times in 1997, described the OAM as "Tom Harkin's folly". In 1995, Wayne Jonas, a promoter of homeopathy and political ally of Harkin, became the director of the OAM, and continued in that role until 1999. In 1997, the NCCAM budget was increased from $12 million to $20 million annually. From 1990 to 1997, use of alternative medicine in the US increased by 25%, with a corresponding 50% increase in expenditures. The OAM drew increasing criticism from eminent members of the scientific community with letters to the Senate Appropriations Committee when discussion of renewal of funding OAM came up. In 1998, the President of the North Carolina Medical Association publicly called for shutting down the OAM. In 1998, NIH director and Nobel laureate Harold Varmus came into conflict with Harkin by pushing to have more NIH control of alternative medicine research. The NIH Director placed the OAM under stricter scientific NIH control.
Sources: en.wikipedia.org
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.
Its sequence corresponds to the 4-10 region of corticotropin extended by three residues. This fragment lacks the region responsible for adrenal steroid release, so it is explored for neural rather than hormonal effects. The relationship explains the compound's classification among ACTH-derived peptides.
It holds approval in Russia for several neurological indications as a nasal spray or drop formulation. Regulatory agencies in the United States and the European Union have not approved it. Products sold elsewhere are generally labeled for research use only.
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.